Liensinine attenuates inflammatory response and oxidative stress by activation of Nrf2/HO- 1 signaling in L-NAME-induced gestational hypertension

Pregnancy-induced hypertension (PIH) is a serious condition that can affect pregnant women after 20 weeks of gestation, which leads to preeclampsia, eclampsia, or even organ damage. Liensinine exhibits a diverse array of biological activities, encompassing anti-arrhythmic, anti-cancer, anti-hypertensive, and anti-pulmonary fibrotic properties. However, the role of Liensinine remains uncharacterized in PIH. Wistar rats were induced by L-NAME to establish the PIH model. The mean arterial pressure and urine protein were measured for hypertension evaluation. The reverse transcription quantitative PCR and Western blot analyses were used for mRNA and protein levels determination, respectively. In addition, H&E staining and TUNEL staining were performed to assess histological changes. Liensinine improved hypertensive symptoms of L-NAME-induced rats by decreasing mean arterial pressure. Besides, Liensinine ameliorated the pregnancy outcomes of L-NAME-induced rats. In addition, Liensinine suppressed inflammatory response and oxidative stress injury in PIH rats. Moreover, Liensinine promoted the release of growth factors including PIGF and VEGF in PIH rats. Furthermore, Liensinine improved pathological changes of placenta tissue and inhibited cell Apoptosis. Mechanistically, Liensinine activates Nrf2/HO- 1 signaling by upregulating Nrf2 and HO- 1 protein levels. Liensinine attenuated inflammatory response and oxidative stress by activation of Nrf2/HO- 1 signaling in PIH.

Inflammatory response; Liensinine; Nrf2/HO- 1 signaling; Oxidative stress; PIH.